Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Himension Capital Singapore PTE. LTD.

Himension Capital Singapore PTE. LTD. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,169 shares of the biopharmaceutical company’s stock after purchasing an additional 2,984 shares during the quarter. Himension Capital Singapore PTE. LTD.’s holdings in Alnylam Pharmaceuticals were worth $4,357,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $895,816,000. Qube Research & Technologies Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $369,943,000. AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after acquiring an additional 555,759 shares during the last quarter. Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Alnylam Pharmaceuticals by 2,221.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company’s stock valued at $187,116,000 after acquiring an additional 392,668 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Bank of America reduced their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research note on Friday, July 10th. Finally, Chardan Capital reiterated a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $455.31.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $271.37 on Wednesday. The firm has a market cap of $36.23 billion, a price-to-earnings ratio of 74.14 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company’s 50-day moving average is $293.50 and its two-hundred day moving average is $318.80. Alnylam Pharmaceuticals, Inc. has a 12-month low of $266.27 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.44) earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.3 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.